Back to News
Market Impact: 0.3
Myriad Genetics Reports Third Quarter 2026 Financial Results and Announces Agreement to Sell Prenatal Health Business
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, up 6% sequentially but down 1% year over year. The company recorded an operating loss of $39.9 million; the provided article text contains no further results or outlook details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
MYGN-0.20
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook